JUN 26, 2018 07:55 PM PDT

Genomic Markers Identified for Infant Soft Tissue Tumors

Epidermal Growth Factor Receptor (EGFR) helps maintain cellular growth and division normally but can become mutated, as in the case with some cancers, so that too many receptors allow exponential, uncontrolled cellular growth and division resulting in a tumor.  EGFR is a transmembrane kinase glycoprotein; its gene locus is found at 7p11.2 and is commonly associated with multiple different cancers as part of gene rearrangements whereby the EGFR signaling pathway becomes deregulated.  EGFR is implicated and/or found in many cancers including lung, breast, head, neck, and colorectal.

B-Raf is another kinase protein associated with processing mitogenic signals between the cell membrane and the nucleus of a cell and its enzymatic activity has been associated with Epidermal Growth Factor and Human Growth Factor ligands.  The gene BRAF is located at 7q34 and is considered a proto-oncogene; there is significant literature outlining the present of mutations and rearrangements involving BRAF resulting in a multitude of cancers including melanoma and colorectal cancer.

A new article from Nature Communications published on June 18, 2018 now outlines a newly discovered connection between multiple different infant soft tissue tumors and these two specific genes.  Childhood tumors, especially those in infancy are often confined to age and developmental stage but little has been known about their etiology and therefore, how to best treat them.  Congenital mesoblastic nephroma (CMN) is renal malignancy in children under 6 months old.  Infantile fibrosarcoma (IFS) is comprised of mutated spindle fiber cells often in the soft tissues of the extremities or abdominal region in an infant.  The researchers examined similar soft tissue tumors for the presence of EGFR or BRAF rearrangement as a diagnostic marker and found that in all CMN specimens evaluated, there was a single in-frame internal tandem duplication (ITD) within the EGFR domain.  The EGFR-ITD was not observed in other tumor types like glioma or adenocarcinoma of the lung.  Additionally, the group discovered mutations in the BRAF gene in some CMN cases also.  A mutated fusion protein as a result of BRAF rearrangement has been observed in some IFS patients but has not been seen in CMN. 

Genomic findings can be groundbreaking for the course of cancer treatments used and for the future development of novel treatments; basing clinical and therapeutic decisions on the mutations present, rather than on the phenotypic findings, is changing the practice of oncology.  For infants with CMN and EGFR-ITD, already existing treatments are available which target EGFR mutations previously identified in other cancers.  This is also true for IFS where a BRAF mutation is the driver.

Sources: Nature Communications, Oncology Reports, Wellcome Sanger Institute, American Society of Clinical Oncology, Expert Opinion on Therapeutic Targets,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
AUG 21, 2018
Health & Medicine
AUG 21, 2018
First, They Came for the Straws...Now the Soda?
Bans on plastic straws and utensils are all over the news recently. While taking care of the planet is crucial, some critics say that banning plastic straw...
AUG 26, 2018
Cancer
AUG 26, 2018
Can antireflux surgery prevent Esophageal cancer?
Heartburn or gastroesophageal reflux disease (GERD) is a widespread health problem affecting 10 to 20% of adults in Western populations. If GERD left untre...
OCT 04, 2018
Videos
OCT 04, 2018
Zebrafish as Metastatic Cancer Model
Another Koch Institute Image Award winner from 2018 is presented in this video from MIT....
OCT 06, 2018
Drug Discovery
OCT 06, 2018
New Class of Drugs for Breast Cancer Therapy
Scientists at Stevens Institute of Technology have designed a new class of molecules that may hold the potential to add to the arsenal of drugs actively be...
OCT 21, 2018
Technology
OCT 21, 2018
New Technology Detects Early-Stage Lung Cancer
According to recent research published in the Journal of Molecular Diagnostics, outcomes of patients with non-small-cell lung carcinoma (NSCLC) may be impr...
DEC 05, 2018
Cancer
DEC 05, 2018
Zika virus as a weapon against brain cancer
Glioblastoma is the most aggressive type of Brain Cancer with an average survival rate of less than two years with treatment. So what if there could be a cure for this type of cancer....
Loading Comments...